CompletedNo phase
Validation of New Prognostic Biomarkers in Patients With Decompensated Cirrhosis
Key facts
- Who runs it
- European Foundation for Study of Chronic Liver Failure
- Where
- France, Germany, Italy, Spain, and United Kingdom9 sites in 5 countriesChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 189 people enrolled
- Started
- 1 Mar 2025
- Ended
- 1 Sept 2026
- Type of study
- Observational
- Record updated
- 10 September 2026
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Age between 18 and 80 years
- Patients with decompensated cirrhosis admitted to hospital due to AD according to the EASL-CLIF criteria (rapid onset of ascites, hepatic encephalopathy, portal hypertensive- related gastrointestinal bleeding, bacterial infection, or any combination of these), including those who presented ACLF during hospitalization
- Recovery from AD and expected to be discharged within the next 48 hours
Who cannot take part
- Previous liver or other organ transplantation
- Patients with TIPS or other surgical porto-caval shunts
- Active malignancy (except for hepatocellular carcinoma within the Milan criteria or nonmelanocytic skin cancer)
- Antiviral treatment for hepatitis C, B and delta initiated in the last 6 months or planned to be initiated in the following 6 months
- HIV positive (except undergoing treatment and who do not exhibit clinical manifestations of AIDS)
- Ongoing alcohol use disorder with an expected low adherence to prescriptions as judged by physician
- Chronic organic renal failure stage IV and V or estimated Glomerular Filtration Rate <20 ml/min according to the MDRD equations
- Chronic heart failure NYHA class III or IV
- Pulmonary disease GOLD III or IV
- Patients with a history of significant extrahepatic disease with life expectancy <6 months
- Severe psychiatric disorders
- Admission for planned diagnostic or therapeutic procedures
- Pregnancy and breast-feeding
- Expected low adherence to study protocol as judged by physician
- Patients who cannot provide written informed consent or refuse to participate
This trial has no sites in United States.
It has sites in 5 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
The study aims to test the effectiveness of new biomarkers (measurable molecules in our body) in predicting the health outcome of patients with liver cirrhosis discharged from the hospital after a serious complication of the disease
The group in the trial
- Patients with Decompensated Liver Cirrhosis
Patients eligible for this study will be patients with decompensated cirrhosis expected to be discharged from the hospital within 48 hours after an index admission for AD according to the EASL-CLIF criteria
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Validation of New Prognostic biomarkerRs in Patients With cirrhOsis diScharged After a hosPitalization Due to acutE deCompensation or acuTe-on-chronic Liver Failure
- Record updated
- 10 September 2026